Category Archives: Potential Treatments

Ariad files FDA application and gets acquired

As of August 30, 2016 Arriad had files its new drug application with the FDA for brigatinib. As of Oct 31, 2016 the FDA granted ARIAD’s request for Priority Review and has set an action date of April 29, 2017. As of January … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Regulatory applications & approvals | Leave a comment

Update on Novartis and Ariad trials

As of Dec. 6, 2016 Novartis and Ariad announced research updates In Phase III study by Novartis on Zykadia® (ceritinib) as a first-line treatment, they found a 45% reduction in the risk of disease progression. The study found a median progression free survival … Continue reading

Posted in Anaplastic Large-Cell Lymphomas, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research | Leave a comment

Abstract 9007 on Brigatinib update

The initial write up of the abstract 9007 was posted on May 19. This update covers about 3 more months of data and brain mets. Arm A (90 mg) median Progression Free Survival (PFS) increased from 8.8 months to 9.2 … Continue reading

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Outcomes for ALK+ patients

Abstract e20550 is from Spain and involves 49 patients. Patients took 6 different ALK inhibitors. The abstract concluded “ALK+ patients who received targeted agents have prolonged survival despite brain metastases…. ALK inhibitors improve intracranial response rate and survival.”

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Discontinuing Crizotinib treatment

Abstract e20610 is from Canada and covers 97 patients. Post Crizotinib treatment 43% received Ceritinib, 20% received chemo and 37% received no additional treatment. Median overall survival was: 0.9 months for those who received no additional treatment, 7.6 months for … Continue reading

Posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

HSP90 and Crizotinib

Abstract 9059 basically flung that administrating an HSP90 inhibitor at the same time as Crizotinib did not delay the development of resistance to Crizotinib.

Posted in crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Alectinib, mutations, and liquid biopsy

Abstract 9061 pooled data from two clinical trials. 129 patients had biopsies done after Crizotinib but before Alectinib. Plasma samples were available for all 272 patients at baseline and for about 50% at progression. At baseline 13 functional ALK mutations … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Crizotinib and children

Abstract 11509 covers 107 pediatric patients and their tumors. ALK alterations were found in 18 of them (not all are fusion mutations). The ages ranged from 3-16 years. 7 patients were still being treated at the data cut off. At … Continue reading

Posted in crizotinib - Xalkori from Pfizer, Glioblastomas, Neuroblastomas, Potential Treatments, Research, Side Effects | Leave a comment

X-396 update and info on liquid biopsy

Abstract 9056 is an update of info previously published on this site. The study involved 60 patients of whom 30 were ALK+ NSCLC. Of that 30, 19 (60%) had partial responses (PR). 8 patients were Crizotinib naive and of them … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects, X-396 - ensartinib from Xcovrery | Leave a comment

Alectinib Japan trial abstract

Abstract 9008 covers the J-ALEX phase 3 trial comparing Crizotinib (arm A) with Alectinib (arm B) in TKI naive patients. There were 207 patients at 41 centers in Japan randomized between the two arms. Arm A had a median PFS … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment | Leave a comment